Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Regencell Bioscience Holdings Ltd (RGC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: RGC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 836.02% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.60B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.62 | 52 Weeks Range 0.08 - 83.60 | Updated Date 06/29/2025 |
52 Weeks Range 0.08 - 83.60 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Earnings Date
Report Date 2025-06-30 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.11% | Return on Equity (TTM) -43.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8536892836 | Price to Sales(TTM) - |
Enterprise Value 8536892836 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -44.58 | Shares Outstanding 494488992 | Shares Floating 29901744 |
Shares Outstanding 494488992 | Shares Floating 29901744 | ||
Percent Insiders 93.84 | Percent Institutions 0.07 |
Upturn AI SWOT
Regencell Bioscience Holdings Ltd
Company Overview
History and Background
Regencell Bioscience Holdings Ltd. was founded in Hong Kong and went public on the Nasdaq in July 2021. It focuses on research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of medical conditions.
Core Business Areas
- Research and Development: Focuses on developing TCM formulations for various medical conditions.
- Commercialization: Aims to commercialize its developed TCM formulas, particularly for Attention Deficit Hyperactivity Disorder (ADHD).
Leadership and Structure
The leadership team consists of individuals with experience in pharmaceuticals, finance, and business development. The company operates with a relatively small team and relies on collaborations and partnerships.
Top Products and Market Share
Key Offerings
- RGC-COV19: A TCM formula developed to treat COVID-19. Market share data is not publicly available, and the efficacy is disputed. Competitors include pharmaceutical companies such as Pfizer, Merck, and Regeneron.
- ADR-001: A TCM formula intended to treat ADHD. The company has conducted clinical trials for this product, but market share data is currently unavailable. Competitors include pharmaceutical companies producing stimulant and non-stimulant ADHD medications, such as Eli Lilly, Novartis, and Johnson & Johnson.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with companies investing heavily in research and development. TCM faces skepticism and requires rigorous scientific validation for wider acceptance.
Positioning
Regencell is a relatively small player in the pharmaceutical industry, focusing on the niche market of TCM-based treatments. Its competitive advantage lies in its proprietary TCM formulas and knowledge, if proven effective through trials.
Total Addressable Market (TAM)
The global pharmaceuticals market is valued in the trillions of USD. The TAM Regencell is addressing is a small portion targeting ADHD/COVID with TCM, where the total market value is a smaller portion. Its positioning within this TAM is still to be defined, especially due to the uncertainty of ADR-001 and RGC-COV19's efficacy.
Upturn SWOT Analysis
Strengths
- Proprietary TCM formulas
- Potential for novel treatments
- Focus on underserved medical needs
Weaknesses
- Limited financial resources
- Small team size
- Dependence on clinical trial success
- Questionable TCM formula's efficacy and high trial cost
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new markets
- Positive clinical trial results
- Growing interest in alternative medicine
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Negative clinical trial results
- Skepticism surrounding TCM
- Low float and manipulation concerns
Competitors and Market Share
Key Competitors
- PFE
- MRK
- LLY
- NVS
- JNJ
Competitive Landscape
Regencell faces significant disadvantages compared to established pharmaceutical companies due to its limited resources, lack of proven products, and regulatory concerns.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the early stage of development. Growth is dependent on successful clinical trial outcomes.
Future Projections: Future growth projections are highly speculative due to the reliance on successful clinical trial data. Analyst estimates are scarce and unreliable.
Recent Initiatives: Recent initiatives include focusing on clinical trials for ADR-001 and exploring potential partnerships.
Summary
Regencell Bioscience Holdings Ltd. is a high-risk, high-reward investment. It possesses the potential for novel TCM-based treatments, but faces numerous challenges, including limited financial resources, regulatory hurdles, and skepticism towards TCM. The success of the company hinges on the outcomes of its clinical trials. There have been shareholder allegations regarding fraud, further increasing the risk for investors. Further evaluation is necessary to mitigate the risk of investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Third-party Financial Data Providers
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in Regencell Bioscience Holdings Ltd. involves significant risks, including the potential loss of investment. Market Share data from various third party providers.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regencell Bioscience Holdings Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-16 | Founder, Chairman & CEO Mr. Yat-Gai Au | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 12 | |
Full time employees 12 | |||
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.